Clinical trial

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

NCT05412446

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ADAPT6-SPECT Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-05-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Femaleunresolved

Interventions

ADAPT6-SPECTDRUG

Sponsors & collaborators

Tomsk National Research Medical Center of the Russian Academy of Scienceslead sponsor

Uppsala Universitycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05412446 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.